Valopicitabine

DB13920InvestigationalSmall molecule

The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus (HCV) activity. Upon administration, valopicitabine is converted into 2'-C-methylcytidine; upon phosphorylation into its 5-triphosphate form, this metabolite... This blocks viral production of HCV RNA and thus viral replication. [from NCI].

Mechanism: Pharmacologically active on RNA-directed RNA polymerase
Curator reviewed
Formula / weight: C₁₅H₂₄N₄O₆ · 356.379 g/mol (avg)
Code names: NM-283

Resolves to

Compound

UNIII2T0B5G94MCAS640281-90-9ChEMBLCHEMBL393820PubChem6918726

Structure

InChIKeyTVRCRTJYMVTEFS-ICGCPXGVSA-NSMILESCC(C)[C@H](N)C(=O)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N)=NC2=O)[C@]1(C)O

Targets

O39930NS5bP26664Genome polyprotein

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Valopicitabine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account